Company Anacor Pharmaceuticals Inc
Equities
US0324201013
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
2016 | Anacor Pharmaceuticals : received rival bid before Pfizer deal - filing | RE |
2016 | Anacor Pharmaceuticals : Pfizer to buy Anacor in $5.2 billion deal for access to eczema gel | RE |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Douglas Giordano
CEO | Chief Executive Officer | 61 | 16-06-23 |
Chief Tech/Sci/R&D Officer | 77 | 04-01-31 | |
Director/Board Member | - | 16-06-23 | |
General Counsel | 75 | 09-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Douglas Giordano
CEO | Chief Executive Officer | 61 | 16-06-23 |
Bryan Supran
BRD | Director/Board Member | - | 16-06-23 |
Director/Board Member | - | 16-06-23 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 45,366,886 | 42,957,738 ( 94.69 %) | 0 | 94.69 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+3.71% | 43.43B | |
+47.81% | 41.69B | |
+8.85% | 41.31B | |
-10.92% | 27.14B | |
+8.72% | 25.28B | |
-24.56% | 18.47B | |
+29.53% | 12.59B | |
+1.26% | 12.33B | |
+9.15% | 11.03B |
- Stock Market
- Equities
- Stock
- Company Anacor Pharmaceuticals Inc